Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
PLSE vs FEMY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PLSE Captures Overall Composite Edge (40.1 SELL vs 52.6 HOLD), While FEMY Leads 3–2 on Growth & Valuation Pillars
PLSE Overall Winner
6-Pillar Tally: PLSE 2 – 3 FEMY (1 Tie)
Matrix Metrics: PLSE 4 – 3 FEMY
As of Nov 16, 2026, Pulse Biosciences, Inc (PLSE) captures the overall head-to-head institutional edge over Femasys Inc. (FEMY) on higher Unified Composite conviction (40.1/100 SELL vs. 52.6/100 HOLD) after splitting the core matrix 4–3 (led by Growth & Scale, Options & Positioning), while FEMY wins 3–2 across the 6-pillar growth and valuation breakdown. PLSE trades at $46.36 (N/M Forward P/E, -5861.2% operating margin) versus FEMY at $1.28 (N/M Forward P/E, -763.9% operating margin).
- Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. PLSE 40.1/100 SELL), PLSE captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-5861.2% vs. -763.9% operating margin) and revenue trajectory (+359.3% vs. -18.9% YoY).
- Technical & Structure Timing Caution: PLSE trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 40.3); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About PLSE vs FEMY
PLSE
Head-to-Head Winner
Pulse Biosciences, Inc Common Stock (DE)
$46.36
-8.09% 1D
Market Cap
$3.7B
TTM Revenue
$1.5M
Forward P/E
N/M
Beta / 30D Vol
1.71β · 78% Vol
Unified Composite Score
40.1
SELL
Tech 25.0
Fund 46.0
Flow 70.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
FEMY
Femasys Inc. Common Stock
$1.28
-9.86% 1D
Market Cap
$11.9M
TTM Revenue
$2.3M
Forward P/E
N/M
Beta / 30D Vol
4.01β · 72% Vol
Unified Composite Score
52.6
HOLD
Tech 61.0
Fund 62.0
Flow 50.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (PLSE 2 – 3 FEMY)
1. Valuation Multiples
FEMY
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
4.9x
2. Growth & Scale
PLSE
Revenue Growth (YoY)
+359.3%
-18.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$1.5M
$2.3M
Market Cap
$3.7B
$11.9M
3. Profitability & Quality
FEMY
Gross Margin
26.8%
60.9%
Operating Margin
-5861.2%
-763.9%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-60.6%
-425.0%
4. Balance Sheet & Cash Flow
FEMY
Cash Generation (TTM)
-$64M
-$19M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$30M Net Cash
-$658,045 Net Debt (0.65x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
PLSE
Options Structure Phase
CONSOLIDATION
UNCLASSIFIED
Current IV / %ile
73.5% (10th %ile)
N/A (N/A)
Put/Call OI Skew
0.70x (Call-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Instruments & Supplies Operator
Medical Instruments & Supplies Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: PLSE (4) vs FEMY (3)| Institutional Metric | PLSE | FEMY | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $3.7B | $11.9M | PLSE | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +359.3% | -18.9% | PLSE | |
| Operating Margin (TTM) | -5861.2% | -763.9% | FEMY | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -60.6% | -425.0% | PLSE | |
| 52-Week Range Position | 73% ($13–$59) | 17% ($0–$6) | PLSE | |
| Beta / 30D Volatility | 1.71β · 78% Vol | 4.01β · 72% Vol | FEMY | |
| Unified Institutional Score | 40.1 / 100 (SELL) | 52.6 / 100 (HOLD) | FEMY | |
| Trailing 12M Revenue (USD) | $1.5M | $2.3M | Scale | |
| Gross Profit Margin (TTM) | 26.8% | 60.9% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 4.9x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$64M ($30M Net Cash) | -$19M (-$658,045 Net Debt (0.65x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
PLSE +26.76 pp
3M Horizon
PLSE +42.6 pp
6M Horizon
FEMY +171.79 pp
1Y Horizon
PLSE +173.08 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PLSE Revenue | FEMY Revenue | PLSE Op. Margin | FEMY Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2020 | N/A | $0M | N/A | -668.0% | FEMY |
| FY2021 | $0M | $0M | -4443.9% | -706.7% | FEMY |
| FY2022 | $0M | $0M | -8293.9% | -961.7% | FEMY |
| FY2023 | N/A | $0M | N/A | -1353.4% | FEMY |
| FY2024 | N/A | $0M | N/A | -1091.8% | FEMY |
| FY2025 | $0M | $0M | -21982.6% | -767.0% | FEMY |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
PLSE
CONSOLIDATION
Current IV
73.5%
IV Percentile
10th %ile
Put/Call OI Skew
0.70x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact PLSE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
FEMY
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact FEMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
PLSE Moat Profile
Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
FEMY Moat Profile
Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ PLSE vs FEMY Key Questions & Quantitative Answers
As of Nov 16, 2026, Pulse Biosciences, Inc (PLSE) captures the overall head-to-head institutional edge over Femasys Inc. (FEMY) on higher Unified Composite conviction (40.1/100 SELL vs. 52.6/100 HOLD) after splitting the core matrix 4–3 (led by Growth & Scale, Options & Positioning), while FEMY wins 3–2 across the 6-pillar growth and valuation breakdown. PLSE trades at $46.36 (N/M Forward P/E, -5861.2% operating margin) versus FEMY at $1.28 (N/M Forward P/E, -763.9% operating margin). Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. PLSE 40.1/100 SELL), PLSE captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-5861.2% vs. -763.9% operating margin) and revenue trajectory (+359.3% vs. -18.9% YoY). Technical & Structure Timing Caution: PLSE trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 40.3); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PLSE leads the Growth & Scale pillar: PLSE posts +359.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (26.8% gross margin, -5861.2% operating margin), compared with FEMY at -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), PLSE cumulative revenue shifted N/A while FEMY shifted N/A. In operating R&D and SG&A reinvestment, PLSE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FEMY.
FEMY screens cheaper on headline valuation multiples. PLSE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PLSE (-60.6% ROE) versus FEMY (-425.0% ROE) capital efficiency.
In options market volatility and institutional positioning, PLSE carries 73.5% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.70x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.71β · 78% Vol realized risk). By comparison, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
FEMY vs PLSE · Reverse Pair
PLSE vs PTGX
· Sector Peer
PLSE vs AXGN
· Sector Peer
PLSE vs CUE
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking